Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.45 |
| ▸ | CDK1 | P06493 | 9/20 | 0.45 |
| ▸ | CDK4 | P11802 | 9/20 | 0.45 |
| ▸ | CCND1 | P24385 | 9/20 | 0.45 |
| ▸ | IKBKB | O14920 | 8/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | CASK | O14936 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.38 |
| ▸ | STK10 | O94804 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84214 | 0.91 | CDK4 (0.40) | CDK2CDK1CDK4CCND1MAPK8 | |
| SCHEMBL67728 | 0.91 | CDK4 (0.48) | CDK2CDK1CDK4CCND1IKBKB | |
| SCHEMBL67727 | 0.91 | CDK4 (0.48) | CDK2CDK1CDK4CCND1IKBKB | |
| SCHEMBL69453 | 0.91 | CDK4 (0.48) | CDK2CDK1CDK4CCND1IKBKB | |
| SCHEMBL69317 | 0.88 | EIF2AK2 (0.43) | CDK2CDK1CDK4CCND1MAPK8 | |
| SCHEMBL68164 | 0.87 | MAPK14 (0.44) | CDK2CDK1CDK4CCND1MAPK8 | |
| SCHEMBL68690 | 0.85 | CDK2 (0.47) | CDK2CDK1CDK4CCND1MAPK8 | |
| SCHEMBL69402 | 0.85 | CDK2 (0.47) | CDK2CDK1CDK4CCND1MAPK8 | |
| SCHEMBL68689 | 0.85 | CDK2 (0.47) | CDK2CDK1CDK4CCND1MAPK8 | |
| SCHEMBL87624 | 0.85 | MAP3K11 (0.37) | CDK2CDK1CDK4CCND1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | CDK2 20/4885CDK1 53/4885CDK4 12/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | CDK2 34/4885CDK1 55/4885CDK4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.